Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy.

Michal Sarfaty,Min Yuen Teo,Samuel Funt,Chung-Han Lee,David H. Aggen,Neha Ratna,Ashley Marie Regazzi,Andrew Thomas Lenis,Ziyu Chen,Hikmat Al-Ahmadie,Angela Rose Brannon,Michael F. Berger,David B. Solit,Jonathan E. Rosenberg,Dean F. Bajorin,Gopa Iyer

Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy.

2021

Michal Sarfaty
Min Yuen Teo
Samuel Funt
Chung-Han Lee
David H. Aggen
Neha Ratna
Ashley Marie Regazzi
Andrew Thomas Lenis
Ziyu Chen
Hikmat Al-Ahmadie
Angela Rose Brannon
Michael F. Berger
David B. Solit
Jonathan E. Rosenberg
Dean F. Bajorin
Gopa Iyer

e16519Background: The pan-FGFR inhibitor erdafitinib (erda) is FDA-approved for pretreated mUC pts harboring FGFR2/3 alterations. We explored concordance of FGFR3 alt profiles between primary tumor...

Keywords:

Internal medicine
Medicine
Oncology
Primary tumor
Plasma.cfDNA
Concordance

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations